379 related articles for article (PubMed ID: 30536746)
21. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin.
Takahara M; Shiraiwa T; Matsuoka TA; Katakami N; Shimomura I
Endocr J; 2015; 62(1):77-86. PubMed ID: 25328035
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Ito D; Shimizu S; Inoue K; Saito D; Yanagisawa M; Inukai K; Akiyama Y; Morimoto Y; Noda M; Shimada A
Diabetes Care; 2017 Oct; 40(10):1364-1372. PubMed ID: 28751548
[TBL] [Abstract][Full Text] [Related]
23. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
Kashiwagi A; Kazuta K; Goto K; Yoshida S; Ueyama E; Utsuno A
Diabetes Obes Metab; 2015 Mar; 17(3):304-8. PubMed ID: 24919820
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome.
Nagashima S; Wakabayashi T; Saito N; Takahashi M; Okada K; Ebihara K; Ishibashi S
J Diabetes Investig; 2020 Sep; 11(5):1363-1365. PubMed ID: 32100949
[TBL] [Abstract][Full Text] [Related]
25. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
Yamamoto C; Miyoshi H; Ono K; Sugawara H; Kameda R; Ichiyama M; Yamamoto K; Nomoto H; Nakamura A; Atsumi T
Endocr J; 2016 Jun; 63(6):589-96. PubMed ID: 27052123
[TBL] [Abstract][Full Text] [Related]
26. Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
Hedrington MS; Davis SN
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):613-23. PubMed ID: 25643044
[TBL] [Abstract][Full Text] [Related]
27. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
[TBL] [Abstract][Full Text] [Related]
28. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
Seino Y; Yabe D; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
J Diabetes Investig; 2018 Mar; 9(2):332-340. PubMed ID: 28502112
[TBL] [Abstract][Full Text] [Related]
29. Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
Wang H; Yao G; Chen X; Ouyang J; Yang J
Diabetes Res Clin Pract; 2019 Nov; 157():107867. PubMed ID: 31568801
[TBL] [Abstract][Full Text] [Related]
30. Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
Okajima F; Nagamine T; Nakamura Y; Hattori N; Sugihara H; Emoto N
J Diabetes Investig; 2017 May; 8(3):341-345. PubMed ID: 27762088
[TBL] [Abstract][Full Text] [Related]
31. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study.
Tsurutani Y; Nakai K; Inoue K; Azuma K; Mukai S; Maruyama S; Iizuka T; Matsuzawa Y; Saito J; Omura M; Nishikawa T
Diabetes Obes Metab; 2018 Nov; 20(11):2675-2679. PubMed ID: 29893003
[TBL] [Abstract][Full Text] [Related]
32. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
Diabetes Obes Metab; 2019 Aug; 21(8):1990-1995. PubMed ID: 30993861
[TBL] [Abstract][Full Text] [Related]
33. Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
Kimura T; Sanada J; Shimoda M; Hirukawa H; Fushimi Y; Nishioka M; Kinoshita T; Okauchi S; Obata A; Kohara K; Tatsumi F; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Investig; 2018 Jul; 9(4):875-881. PubMed ID: 29110406
[TBL] [Abstract][Full Text] [Related]
34. Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.
Ishihara H; Yamaguchi S; Sugitani T; Kosakai Y
Clin Drug Investig; 2019 Dec; 39(12):1213-1221. PubMed ID: 31552641
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Nakamura I; Maegawa H; Tobe K; Tabuchi H; Uno S
Expert Opin Pharmacother; 2018 Feb; 19(3):189-201. PubMed ID: 29185822
[TBL] [Abstract][Full Text] [Related]
36. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
37. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease.
Inoue M; Hayashi A; Taguchi T; Arai R; Sasaki S; Takano K; Inoue Y; Shichiri M
J Diabetes Investig; 2019 Jul; 10(4):1004-1011. PubMed ID: 30461221
[TBL] [Abstract][Full Text] [Related]
38. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
Alkabbani W; Gamble JM
Drug Des Devel Ther; 2021; 15():3057-3069. PubMed ID: 34285473
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Maegawa H; Tobe K; Tabuchi H; Nakamura I; Uno S
Expert Opin Pharmacother; 2018 Mar; 19(4):327-336. PubMed ID: 29388470
[TBL] [Abstract][Full Text] [Related]
40. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
Takahashi H; Kessoku T; Kawanaka M; Nonaka M; Hyogo H; Fujii H; Nakajima T; Imajo K; Tanaka K; Kubotsu Y; Isoda H; Oeda S; Kurai O; Yoneda M; Ono M; Kitajima Y; Tajiri R; Takamori A; Kawaguchi A; Aishima S; Kage M; Nakajima A; Eguchi Y; Anzai K
Hepatol Commun; 2022 Jan; 6(1):120-132. PubMed ID: 34558835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
